Ownership and insider activity for Savara Inc. (SVRA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Price
| Price | $5.13 |
| Market Cap | $1.1B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-15 | Lutz Robert Matthew | A-Award | 35,000 | |
| 2026-07-15 | Lutz Robert Matthew | A-Award | 70,000 | $407K |
| 2026-06-22 | Lowrance David L | M-Exempt | 87,650 | $294K |
| 2026-06-22 | Lowrance David L | M-Exempt | 218,750 | $330K |
| 2026-06-22 | Lowrance David L | F-InKind | 53,387 | $294K |
| 2026-06-22 | Lowrance David L | M-Exempt | 12,500 | $56K |
| 2026-06-22 | Lowrance David L | F-InKind | 10,114 | $56K |
| 2026-06-22 | Lowrance David L | F-InKind | 60,057 | $330K |
| 2026-06-22 | Lowrance David L | M-Exempt | 56,937 | $63K |
| 2026-06-22 | Lowrance David L | F-InKind | 11,491 | $63K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $13.4M | $22.1M | $24.3M | $49.8M | $22.9M | $34.0M | $52.1M | $26.6M | $15.1M | $33.2M |
| Short-term Investments | 0 | $72.2M | $86.5M | $72.0M | $59.3M | $127.2M | $73.8M | $135.7M | $181.2M | $202.5M |
| Receivables | $868000 | $1.0M | $1.7M | $1.6M | $1.7M | $1.1M | $954000 | $1.0M | $1.0M | $1.3M |
| Inventory | $337000 | $2.5M | 0 | -$1.6M | 0 | -$1.1M | $2.1M | 0 | 0 | 0 |
| Total Current Assets | $14.6M | $97.9M | $113.3M | $124.1M | $85.1M | $165.0M | $129.0M | $165.9M | $202.1M | $241.6M |
| Property, Plant & Equipment | $793000 | $925000 | $522000 | $352000 | $156000 | $73000 | $51000 | $270000 | $165000 | $100000 |
| Goodwill | $3.1M | $27.1M | $26.9M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $10.5M | $33.6M | $11.4M | $11.1M | $12.2M | $11.3M | $10.7M | $11.0M | $10.3M | $11.6M |
| Total Assets | $28.9M | $159.6M | $152.3M | $136.2M | $97.7M | $176.6M | $139.8M | $177.6M | $212.9M | $253.4M |
| Accounts Payable | $536000 | $2.8M | $3.9M | $3.4M | $2.6M | $1.4M | $1.3M | $3.5M | $4.5M | $5.8M |
| Short-term Debt | 0 | 0 | 0 | $2.0M | 0 | $8.3M | 0 | 0 | 0 | $7000 |
| Total Current Liabilities | $3.5M | $6.0M | $7.3M | $10.9M | $8.2M | $14.7M | $5.9M | $10.6M | $14.7M | $20.4M |
| Long-term Debt | $3.4M | $14.8M | $24.5M | $23.1M | $25.1M | $17.3M | $26.1M | $26.3M | $26.6M | $29.9M |
| Total Liabilities | $64.8M | $40.3M | $152.3M | $34.5M | $33.4M | $32.1M | $32.0M | $37.2M | $41.4M | $50.3M |
| Retained Earnings | -$38.4M | -$68.2M | -$129.7M | -$207.9M | -$257.5M | -$300.5M | -$338.7M | -$393.4M | -$489.2M | -$608.1M |
| Total Equity | -$35.9M | $119.3M | $108.2M | $101.7M | $64.4M | $144.5M | $107.8M | $140.4M | $171.4M | $203.1M |
| Total Debt | $4.5M | $15.3M | $24.6M | $25.6M | $25.3M | $25.8M | $26.1M | $26.5M | $26.7M | $29.9M |
| Net Debt | -$8.9M | -$79.0M | -$86.3M | -$96.2M | -$56.9M | -$135.4M | -$99.7M | -$135.8M | -$169.6M | -$205.8M |
| Working Capital | $11.2M | $91.8M | $106.1M | $113.2M | $76.9M | $150.3M | $123.1M | $155.3M | $187.4M | $221.2M |
Financial Health
| Debt / Equity | 0.21 |
| Current Ratio | 10.13 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 12.07 |
Profitability
| Return on Equity | -90.28% |
| Return on Invested Capital | -82.30% |
| Return on Assets | -72.50% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BCAX · EYPT · GERN · GHRS · KURA · NBTX · PROK
Explore sector: Healthcare · Biotechnology
More sections of SVRA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks